Of the two known forms of intestinal somatostatin, somatostatin-28 (S2
8) and S14, S28 predominates in the distal mucosa, whereas S14 is loca
lized in the foregut. Although S14 release has been well studied, litt
le is known about the factors regulating secretion of S28 from the int
estine. Therefore, fetal rat intestinal cultures, which have been prev
iously demonstrated to synthesize and secrete predominantly S28, were
treated with potential nutrient, neuromodulator/ transmitter, and pept
ide secretagogues (n = 4-6/experiment). Oleic acid dose dependently st
imulated the release of somatostatin-like immunoreactivity (SLI) to 27
2 +/- 81% of the control value at 1.5 X 10(-4) M (P < 0.01). Gel perme
ation analysis (n = 3) demonstrated that this increment was accounted
for not only by an increase in the release of S28, but also by an incr
ease in that of S14, such that the secretion of both peptides was incr
eased in parallel. Of the neuromodulators tested, only the enteric pep
tide gastrin-releasing peptide stimulated intestinal SLI secretion, to
386 +/- 60% of the control value at 10(-6) M (P < 0.001); similar to
oleic acid, the effects on S28 and S14 were equivalent. Galanin, vasoa
ctive intestinal peptide, bethanechol, and epinephrine did not affect
SLI release. The duodenal hormone secretin also stimulated SLI release
to 310 +/- 78% of the control value at 10(-6) M (P < 0.001); however,
secretin caused a preferential release of S14 over that of S28 (S14,
7.8 +/- 2.8-fold; S28, 1.5 +/- 0.1-fold). In contrast, gastrin, cholec
ystokinin, glucose-dependent insulinotropic peptide, neurotensin, pept
ide YY, epidermal growth factor, and transforming growth factor-alpha
had no effect on intestinal SLI release. Thus, luminal nutrients and n
euro/endocrine peptides exert differential effects on S28 release from
the rat intestine compared with those on S14. These findings implicat
e S28 as a distinct regulatory peptide in the physiological setting.